AI stocks crash despite companies like Amazon, Alphabet, and chip manufacturers posting record double-digit growth and Amazon announcing $200 billion infrastructure investment, prompting analysts to declare the selloff a rare once-in-a-decade buying opportunity as the transformative technology remains in early development stages.
NVIDIA launches a $1 billion AI drug discovery lab with pharmaceutical giant Lilly and expands its BioNeMo platform, partnering with major life sciences companies to automate scientific discovery through AI models that predict molecular structures and connect digital agents to robotic laboratory systems.
NVIDIA and Eli Lilly unveil a groundbreaking $1 billion AI co-innovation lab that promises to revolutionize drug discovery by creating a continuous learning system connecting physical laboratories with computational AI for round-the-clock experimentation and pharmaceutical development.
Excelsior Sciences secures $95 million to revolutionize drug discovery by replacing human chemists with AI-powered robots that break down FDA-approved molecules into 'smart bloccs' and reassemble them into new pharmaceutical compounds, promising faster and cheaper development while reshoring manufacturing to the US.
Anthropic launches Claude for Life Sciences, its first specialized AI platform for the sector, promising to slash research tasks from days to minutes by integrating with scientific tools like PubMed and Benchling to accelerate discovery from literature reviews to regulatory submissions.
Cortical Labs launches CL1, the world's first commercial biological computer that harnesses 800,000 lab-grown human neurons to process data with submillisecond response times, offering a $35,000 energy-efficient alternative to traditional computing for pharmaceutical, financial, and AI research applications.
Google's new 27 billion parameter AI model discovers that combining silmitasertib with low-dose interferon can convert immune-resistant 'cold' tumors into 'hot' targets for immunotherapy, with lab tests confirming a 50% boost in immune recognition.
Billionaire Mark Cuban harnesses OpenAI's Sora platform to generate AI videos of himself promoting his pharmaceutical company Cost Plus Drugs, with the viral clips featuring him delivering promotional messages and dancing garnering tens of thousands of views as a cost-free marketing experiment.
Google enhances its Jules AI coding assistant with new command line tools and API support, while Nvidia introduces a revolutionary 4-bit training format that cuts AI training costs, and MIT researchers use generative AI to dramatically accelerate antibiotic discovery from years to much shorter timeframes.
AstraZeneca strikes a massive $555 million partnership with Algen Biotechnologies, combining cutting-edge AI platform 'AlgenBrain' with CRISPR gene technology to revolutionize drug discovery for chronic inflammatory diseases and unlock next-generation immunology therapies.